company background image
LZAG.F logo

Lonza Group OTCPK:LZAG.F Stock Report

Last Price

US$592.00

Market Cap

US$43.9b

7D

8.9%

1Y

3.8%

Updated

26 Mar, 2024

Data

Company Financials +

LZAG.F Stock Overview

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally.

LZAG.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Lonza Group AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lonza Group
Historical stock prices
Current Share PriceCHF592.00
52 Week HighCHF673.62
52 Week LowCHF336.03
Beta0.61
1 Month Change11.17%
3 Month Change42.31%
1 Year Change3.79%
3 Year Change6.04%
5 Year Change92.21%
Change since IPO1,133.33%

Recent News & Updates

Recent updates

Shareholder Returns

LZAG.FUS Life SciencesUS Market
7D8.9%-1.9%0.6%
1Y3.8%3.9%29.5%

Return vs Industry: LZAG.F matched the US Life Sciences industry which returned 3.4% over the past year.

Return vs Market: LZAG.F underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is LZAG.F's price volatile compared to industry and market?
LZAG.F volatility
LZAG.F Average Weekly Movement6.9%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: LZAG.F's share price has been volatile over the past 3 months.

Volatility Over Time: LZAG.F's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
189718,000Albert Baehnyhttps://www.lonza.com

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.

Lonza Group AG Fundamentals Summary

How do Lonza Group's earnings and revenue compare to its market cap?
LZAG.F fundamental statistics
Market capUS$43.86b
Earnings (TTM)US$723.34m
Revenue (TTM)US$7.43b

60.6x

P/E Ratio

5.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LZAG.F income statement (TTM)
RevenueCHF6.72b
Cost of RevenueCHF4.77b
Gross ProfitCHF1.95b
Other ExpensesCHF1.29b
EarningsCHF654.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 03, 2024

Earnings per share (EPS)8.80
Gross Margin29.00%
Net Profit Margin9.74%
Debt/Equity Ratio29.4%

How did LZAG.F perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

45%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.